Results 61 to 70 of about 26,977 (247)
ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul +13 more
wiley +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
International Journal of Cardiology: Heart & Vasculature, 2019 Backgrounds: Some patients who undergo implantation of cardiac resynchronization therapy with defibrillator (CRT-D) survive long enough, thus requiring CRT-D battery replacement.
Michio Ogano +7 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
Indian Pacing and Electrophysiology Journal, 2019 Dextrocardia is a congenital anomaly where the heart is abnormally located in the right hemithorax. In these patients, the implementation of transvenous implantable cardioverter-defibrillator (TV-ICD) can be technically challenging and pose a higher risk
Ariel González-Cordero +2 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
A Woman with Electrocardiographic ST-segment Elevation After a Road Traffic Accident
Indian Journal of Clinical CardiologyWe present the case of a woman in her mid-50s with suspected arrhythmic syncope while she was driving owing to fever-induced Brugada syndrome. The patient was appropriately managed with prompt antipyretic treatment and an implantable cardioverter ...
Andreas Y. Andreou +2 more
doaj +1 more source
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source
FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran +10 more
wiley +1 more source
Diabetes & Vascular Disease Research, 2020 Introduction: Patients with diabetes mellitus are known to carry an increased risk for surgical site infections and perioperative complications. The subcutaneous implantable cardioverter defibrillator is an established treatment option in patients at ...
Elif Kaya +6 more
doaj +1 more source